{"title":"Poor Results in a Phase 3 Trial Deal a Blow to a Promising, Controversial ALS Drug","authors":"Stacey Burling","doi":"10.1097/01.nt.0001012792.20466.07","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19197,"journal":{"name":"Neurology Today","volume":" 0","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.nt.0001012792.20466.07","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}